Quality-of-Life and Surgical Outcomes for Breast Cancer Patients Treated with Therapeutic Reduction Mammoplasty Versus Mastectomy with Immediate Reconstruction

Stein, Michael J.; Karir, Aneesh; Arnaout, Angel; Roberts, Amanda; Cordeiro, Erin; Zhang, Tinghua; Zhang, Jing

doi:10.1245/s10434-020-08574-8

Cited by 26 publications

(17 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study reported that breast-conserving surgery was associated with less complications and need for revisional surgery in comparison to both allogenous and autogenous reconstruction methods. Furthermore, breast conserving surgery led to better sexual well-being and satisfaction with the breast [11]. Our study complements the above mentioned studies by investigating breast cancer patients HRQOL in a prospective manner with both breast cancer specific (EORTC QLQ-C30-BR23) and generic (15D) HRQoL instruments.…”

Section: Introductionsupporting

confidence: 60%

Surgery and health-related quality of life – A prospective follow up study on breast cancer patients in Finland

Rautalin

Jahkola

Roine

2021

European Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 60%

Surgery and health-related quality of life – A prospective follow up study on breast cancer patients in Finland

Rautalin

Jahkola

Roine

2021

European Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…One study reported complications from a previously validated list (National Surgical Quality Improvement Program) 29 . A minority of studies classified complications according to morbidity, as ‘major’ or ‘minor’ ( n = 14, 9.5 per cent) 1 , 14 , 28 , 30–38 although definitions of ‘major’ varied, for example, necessitating surgical management or readmission. Only four (2.7 per cent) studies used the validated Clavien–Dindo classification 39–42 .…”

Section: Resultsmentioning

confidence: 99%

“…PROMS which include (but are not limited to) aesthetic outcomes are described in this section. A total of 17 studies used at least one validated outcome measurement tool 30 , 43 , 47 , 54 , 56 , 57 , 61 , 67 , 85 , 94 , 100 , 102 , 104 , 105 , 117 , 124 , 139 , mostly frequently the BREAST-Q ( n = 12) 30 , 43 , 56 , 57 , 61 , 67 , 85 , 100 , 104 , 105 , 139 , 140 using three different modules where specified ( Table 6 ). Two studies modified the BREAST-Q reduction module to accommodate the TM population by adding items relating to breast cancer treatment and reconstruction 43 , 104 .…”

Section: Resultsmentioning

confidence: 99%

Outcome reporting in therapeutic mammaplasty: a systematic review

et al. 2021

View full text Add to dashboard Cite

Background Therapeutic mammaplasty (TM) is an oncological procedure which combines tumour resection with breast reduction and mastopexy techniques. Previous systematic reviews have demonstrated the oncological safety of TM but reporting of critically important outcomes, such as quality of life, aesthetic and functional outcomes, are limited, piecemeal or inconsistent. This systematic review aimed to identify all outcomes reported in clinical studies of TM to facilitate development of a core outcome set. Methods Medline, EMBASE, CINAHL and Web of Science were searched from inception to 5 August 2020. Included studies reported clinical outcomes following TM for adult women. Two authors screened articles independently for eligibility. Data were extracted regarding the outcome definition and classification type (for example, oncological, quality of life, etc.), time of outcome reporting and measurement tools. Results Of 5709 de-duplicated records, 148 were included in the narrative synthesis. The majority of studies (n = 102, 68.9 per cent) reported measures of survival and/or recurrence; approximately three-quarters (n = 75, 73.5 per cent) had less than 5 years follow-up. Aesthetic outcome was reported in half of studies (n = 75, 50.7 per cent) using mainly subjective, non-validated measurement tools. The time point at which aesthetic assessment was conducted was highly variable, and only defined in 48 (64.0 per cent) studies and none included a preoperative baseline for comparison. Few studies reported quality of life (n = 30, 20.3 per cent), functional outcomes (n = 5, 3.4 per cent) or resource use (n = 28, 18.9 per cent). Conclusion Given the oncological equivalence of TM and mastectomy, treatment decisions are often driven by aesthetic and functional outcomes, which are infrequently and inconsistently reported with non-validated measurement tools.

show abstract

“…The biogenesis and development of breast cancer are associated with changes in multiple genes, including the activation of oncogenes and the loss of tumor suppressor gene function, which result in unregulated cell proliferation, differentiation, and inhibition of apoptosis (15)(16)(17)(18). Current clinical efforts are devoted to identifying highly-specific breast cancer-related genes.…”

Section: Discussionmentioning

confidence: 99%

The expression and clinical significance of signal transducer and activator of transcription 3, tumor necrosis factor α induced protein 8-like 2, and runt-related transcription factor 1 in breast cancer patients

Lan

Jin²,

et al. 2021

Gland Surg

View full text Add to dashboard Cite

Background: This study explored the expression and clinical significance of signal transducer and activator of transcription 3 (STAT3), tumor necrosis factor α induced protein 8-like 2 (TIPE2), and runt-related transcription factor 1 (RUNX1) in breast cancer tissue.Methods: From October 2014 to October 2017, 68 breast cancer patients (68 breast cancer tissue specimens) who underwent a radical mastectomy in our hospital were set as the observation group and the corresponding normal tissue 3 cm away from the cancer tissue was selected as the control group. The expression levels of STAT3, TIPE2, and RUNX1 in the two groups were compared via immunohistochemical staining. Multiple logistic regression was then used to analyze the related risk factors affecting the 2-year prognosis of breast cancer patients. The receiver operating characteristic (ROC) curve was then plotted and the area under the ROC curve was calculated. The predictive values of STAT3, TIPE2, and RUNX1, and the predictive value of the three transcription factors combined on the 2-year prognostic survival of breast cancer patients were determined.Results: (I) In the observation group, the positive expression of STAT3 and the negative expression of TIPE2 and RUNX1 were significantly higher than those in the control group (P<0.05). (II) Of the 68 patients, 51 survived within 2 years and 17 patients died. Positive STAT3 expression, negative TIPE2 expression, negative RUNX1 expression, poor histological differentiation, TNM stage Ⅲ-Ⅳ, and distant metastasis were all identified as factors that can affect the 2-year prognosis of breast cancer patients (P<0.05). (III) The ROC curve analysis examining the 2-year prognostic survival of breast cancer patients showed that the area under the curve achieved the largest value when the predictive values of STAT3, TIPE2, RUNX1 were combined. Conclusions:The levels of STAT3, TIPE2, and RUNX1 expression in breast cancer tissues were significantly different from that in adjacent normal tissues. This suggested that the combined detection of STAT3, TIPE2, and RUNX1 may improve the rate of early breast cancer diagnosis. Furthermore, STAT3, TIPE2, and RUNX1 may be useful in evaluating the prognosis of the patients with breast cancer.

show abstract

Quality-of-Life and Surgical Outcomes for Breast Cancer Patients Treated with Therapeutic Reduction Mammoplasty Versus Mastectomy with Immediate Reconstruction

Cited by 26 publications

References 38 publications

Surgery and health-related quality of life – A prospective follow up study on breast cancer patients in Finland

Surgery and health-related quality of life – A prospective follow up study on breast cancer patients in Finland

Outcome reporting in therapeutic mammaplasty: a systematic review

The expression and clinical significance of signal transducer and activator of transcription 3, tumor necrosis factor α induced protein 8-like 2, and runt-related transcription factor 1 in breast cancer patients

Contact Info

Product

Resources

About